Introduction

The Acetylcysteine 20 % w/v Nebulizing Solution discussed in the Pharmaceutics component of this assignment requires a validated analytical method to confirm that the active pharmaceutical ingredient is present in the labelled concentration and has not degraded during the manufacturing process or storage. Quantification of acetylcysteine content is a critical quality control measure because acetylcysteine's free thiol (-SH) group is highly reactive and susceptible to oxidation, forming inactive degradation products such as the disulfide dimer, N,N′-diacetylcystine (Pfizer, 2023). Therefore, an assay must be both accurate and sufficiently selective to distinguish intact drug from these degradation products.

Since no British Pharmacopeia Monograph exits specifically for an acetylcysteine nebulizing solution, the methodology described in the BP Monograph for Acetylcysteine Injection was adapted for this essay (British Pharmacopeia Commission, 2022). This is the closest official recognised sterile aqueous acetylcysteine preparation.

This section outlines the analytical procedure developed to quantify acetylcysteine in the nebulizing solution using High-Performance Liquid Chromatography (HPLC) with UV detection. HPLC was selected for its high sensitivity and specificity, allowing clear resolution of the intact drug from potential degradation products and excipient interference (British Pharmacopoeia Commission, 2022). The following sections define the sample, describe the sampling procedure, and detail sample preparation, dilution and the full analytical method. To strengthen the confidence in this assay's accuracy and results, the HPLC result is further cross validated in the assay validation section against iodometric titration, which is the official British Pharmacopeia assay method for acetylcysteine content (British Pharmacopoeia Commission, 2022).